-+ 0.00%
-+ 0.00%
-+ 0.00%

DESIGN THERAPEUTICS INC - PHASE 1 SINGLE-ASCENDING DOSE TRIAL SHOWS DT-216P2 WELL-TOLERATED

Reuters·06/04/2025 11:00:01

Please log in to view news